A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2026-02-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open label, multi center, dose escalation and expansion, safety,
tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients
with advanced or metastatic cancer.